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Background: It has been suggested that different hepatitis B virus (HBV) genotypes may have distinct virological
characteristics that correlate with clinical outcomes during antiviral therapy and the natural course of infection.
Hydrodynamic injection (HI) of HBV in the mouse model is a useful tool for study of HBV replication in vivo.
However, only HBV genotype A has been used for studies with HI.
Methods: We constructed 3 replication-competent clones containing 1.1, 1.2 and 1.3 fold overlength of a HBV
genotype B genome and tested them both in vitro and in vivo. Moreover, A HBV genotype B clone based on
the pAAV-MCS vector was constructed with the 1.3 fold HBV genome, resulting in the plasmid pAAV-HBV1.3B
and tested by HI in C57BL/6 mice. Application of siRNA against HBx gene was tested in HBV genotype B HI
mouse model.
Results: The 1.3 fold HBV clone showed higher replication and gene expression than the 1.1 and 1.2 fold HBV
clones. Compared with pAAV-HBV1.2 (genotype A), the mice HI with pAAV-HBV1.3B showed higher HBsAg and
HBeAg expression as well as HBV DNA replication level but a higher clearance rate. Application of two plasmids
pSB-HBxi285 and pSR-HBxi285 expressing a small/short interfering RNA (siRNA) to the HBx gene in HBV
genotype B HI mouse model, leading to an inhibition of HBV gene expression and replication. However, HBV
gene expression may resume in some mice despite an initial delay, suggesting that transient suppression of HBV
replication by siRNA may be insufficient to prevent viral spread, particularly if the gene silencing is not
highly effective.
Conclusions: Taken together, the HI mouse model with a HBV genotype B genome was successfully established
and showed different characteristics in vivo compared with the genotype A genome. The effectiveness of gene
silencing against HBx gene determines whether HBV replication may be sustainably inhibited by siRNA in vivo.
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Hepatitis B virus (HBV) causes acute and chronic infec-
tion in the human liver and subsequently hepatic cirrhosis
and hepatocellular carcinoma (HCC) that severely affects
human health [1-3]. Although a highly effective vaccine is
now available for the prevention of new HBV infec-
tions, about 400 million people worldwide have already
been chronically infected and suffer from chronic liver
injury [4].
An immunologically well-characterized small animal
model for HBV infection remains unavailable due to the
strict host specificity of HBV infection, which greatly
hampers HBV-related research. The laboratory mouse is
genetically and immunologically defined, and a large
collection of genetically modified animals exists. However,
mice can not be infected with HBV. Several lines of trans-
genic mice with replication competent HBV genomes have
been established and represented to be powerful tools for
HBV research [5]. However, HBV replication in the trans-
genic mice is generated from the integrated HBV sequence
harbored in all hepatocytes, which is different from what
occurs during a natural infection [5-8]. The presence of
HBV genomes in these mouse lines inevitably induces
immune tolerance to the HBV antigens. In addition, the
capability of production of transgenic mouse model is
not readily available in ordinary laboratory conditions.
Transplant mouse models were established and used
for different studies [9-11]. However, the models are
based on immunodeficient mouse strains and difficult
to handle in the laboratory.
Hydrodynamic injection (HI) of replication-competent
HBV DNA into the tail veins of mice can establish HBV
replication in the mouse liver [12,13]. In 40% of injected
C56BL/6 mice, the persistence of HBV surface antige-
nemia (HBsAg) was greater than 6 months. HBV persis-
tence is determined by the mouse genetic background and
plasmid backbone [12]. The HBV HI mouse model is a
highly interesting model for testing vaccination strategies
and mechanisms of viral persistence [14-18]. This model
may be used to the study replication competence of HBV
constructs [15]. Previously, the established HBV HI mouse
models were based on HBV genotype A replication-
competent clones [12,13]. As HBV genotypes B and C are
highly prevalent in Asia and may have distinct virological
characteristics that correlate with clinical outcomes in the
natural course of infection and antiviral therapy, it is
warranted to establish HBV HI mouse models with
characterized HBV strains.
Patients with chronic HBV infection are currently
treated with interferon alpha (IFN-α) or nucleotide
analogs such as entecavir and tenofovir. However, the
current therapies have only a limited success rate and
frequent viral recurrence after cessation of therapy,
therefore, new antiviral strategies are required [19,20].RNA interference has been developed as potential thera-
peutic approaches [21-24]. In previous studies, siRNAs
targeting different regions of the HBV genome were
used. The HBx gene encodes a small non-structural
protein that has diverse functions and is required for
HBV efficient replication [25,26]. The HBx mRNA con-
tains the common sequence of the four transcripts of
HBV [25,27,28], which makes it a potentially useful
target for antiviral therapy.
In this study, we addressed the question whether a repli-
cation competent HBV genotype B clone could replicate
transiently and persistently in HI mouse model. Plasmids
pSB-HBxi285 (non-viral vector) and pSR-HBxi285 (retro-
viral vector) that express siRNA targeting the HBx gene
were constructed. Using these constructs, we asked how
the gene silencing by HBx siRNA of genotype B influences
the course of HBV replication and persistence in the HI
mouse model.
Results
Identification of different folds of HBV DNA expression
plasmids
The 1.1, 1.2 and 1.3 fold over-length HBV genome DNA
including nt 1658-3215-1986, nt 1360-3215-1986 and nt
1040-3215-1986 were cloned into the pBluesript II KS (+)
vector separately. The construction procedure is shown in
Additional file 1: Figure S1A and schematic representation
of the 1.1, 1.2 and 1.3 fold HBV genome are shown in
Additional file 1: Figure S1B. The plasmids were analyzed
by restriction enzyme digestion with PstI and SacI. PstI
and SacI restriction digestion of pBS-HBV1.1B, pBS-
HBV1.2B and pBS-HBV1.3B resulted in the appearance of
additional bands of 3.5, 3.8 and 4.2 kb in addition to the
pBluescript II KS (+) vector, respectively (Additional file 2:
Figure S2). Consistently, PstI restriction digestion of pBS-
HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B confirmed that
these vectors have the sizes of 6.5, 6.8 and 7.2 kb, respect-
ively (Additional file 2: Figure S2). The HBV 1.3 fold over
length genome DNA was amplified and sub-cloned into
the NotI site of the pAAV-MCS vector (Agilent tech-
nologies, La Jolla, USA). The construction procedure of
pAAV-HBV1.3B is shown in Additional file 1: Figure S1C.
The plasmid pAAV-HBV1.3B was identified by NotI
restriction digestion and an additional band of 4.16 kb
(data not shown).
pBS-HBV1.3B shows high replication competence both
in vitro and in vivo
To investigate the functionality of pBS-HBV1.1B, pBS-
HBV1.2B and pBS-HBV1.3B in hepatoma cells, the
plasmids were transfected into Huh-7 cells. At 48 h post-
transfection, the culture supernatants of the transfected
cells were harvested and subjected to HBsAg and HBeAg














Figure 1 Comparison of the in vitro and in vivo replication competence of pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B. 0.8 μg of
plasmid DNA were transfected into Huh-7 cells which were seeded in 24-well plates at approximately 60% confluence and 10 μg of plasmid DNA
were injected into the tail veins of BALB/c mice. Each group included 10 mice. (A) Titers of HBsAg (ng/ml) and HBeAg (NCU/ml, National Clinical
Unit/ml,) in the supernatants of pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B transfected Huh-7 cells at 48 h post-transfection. The data were
analyzed by one-way ANOVA, and the differences were statistically significant (* and Δ mean p < 0.01). (B) Real-time PCR detection of HBV DNA in
mouse sera at day 7 after HI of pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B (the number of the mice ≥ 3). The data were analyzed by one-way
ANOVA, and the differences were statistically significant (* means p < 0.01). (C) Immunohistochemical staining of the liver sections for HBcAg in
hepatocytes of pBS-HBV1.1B- (1), pBS-HBV1.2B- (2), pBS-HBV1.3B- (3) and pBS (4)-injected mice at 7 day post injection (Original magnification: 200X).
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transfected Huh-7 cells were significantly higher than
those with the of pBS-HBV1.1B and pBS-HBV1.2B
plasmids (p < 0.01).
To further compare the replication competence of
pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B in vivo,
BALB/c mice were subjected to HI with these plasmids.
Each group contained 10 mice. At 7 dpi, mouse serum
samples were collected for HBV DNA quantification.
The liver tissue was collected for immunohistochemical
staining of HBcAg. Figure 1B showed that HI with pBS-
HBV1.3B resulted in a significantly higher HBV DNA
level in mouse serum samples compared with HI withpBS-HBV1.1B and pBS-HBV1.2B (p < 0.01). Immuno-
staining of HBcAg demonstrated that HBcAg positive
hepatocytes could be detected in the mouse liver after
HI with each of the three plasmids but absent in the
control mice. Moreover, the HBcAg positive hepatocytes
were most abundant in the mouse liver of pBS-HBV1.3B
transfected mice (Figure 1C).
The influence of the host genetic background and
plasmid backbone on HBV persistence
It is reported that HBV persistence after HI in mice
depends on the host genetic background and plasmid
backbone [12].
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cloned into pAAV vector to generate pAAV-HBV1.3B.
HI with pAAV-HBV1.3B was performed in C57BL/6
mice to examine whether this HBV isolate of genotype B
is able to establish persistent replication in vivo. In para-
llel, pAAV-HBV1.2 described by Huang et al. (2006) was
used as a reference. pAAV-HBV1.3B group included 14
mice and pAAV-HBV1.2 group included 9 mice. The
serum HBV DNA levels in C57BL/6 mice with pAAV-
HBV1.3B were determined at the indicated time points
up to week 48 and were higher than those in mice with
pAAV-HBV1.2 (Figure 2A).
The liver tissue was collected from C57BL/6 mice
injected with pAAV-HBV1.3B at 70, 168 and 252 dpi or
pAAV-HBV1.2 at 70 dpi, 168 dpi and 340 dpi. HBV
DNA was extracted from the liver tissue samples and
assayed for HBV DNA by Southern blot analysis. Bands
corresponding to the expected size of the input HBV
plasmids and HBV replication intermediates including
relaxed circular (RC) and single-stranded (SS) HBV
DNAs could be detected in the liver of HBsAg-positive
C57BL/6 mice hydrodynamically injected with pAAV-
HBV1.3B or pAAV-HBV1.2 (Figure 2B). HBV replication
intermediates were at a higher level in mice injected
with pAAV-HBV1.2 than in those with pAAV-HBV1.3B.
Intrahepatic HBV DNA levels also detected by real-time
PCR and the results were consistent with the Southern-
blot results (Figure 2C). Immunohistochemical staining
of the liver sections for HBcAg revealed that both
cytoplasmic and nucleic HBcAg were detected in the
liver of HBsAg-positive mice hydrodynamically injected
with pAAV-HBV1.3B or pAAV-HBV1.2 (Figure 2D). In
contrast, no HBcAg positive cell was present in the liver
of the control mice and HBsAg-negative mice. All
results obtained in this experiment indicate that HBV
genotype B construct was replication competent in the
mouse liver.
To investigate whether the vector backbone and the
host genetic background also influence persistence of
the HBV isolate of genotype B, 10 μg of the pBS-HBV1.3B
or pAAV-HBV1.3B plasmids were injected hydrodynami-
cally into the tail veins of male C57BL/6 or BALB/c mice.
Each group included 5 mice. After HI, the mice were
regularly bled and the temporal changes in HBsAg,
HBeAg, HBcAb, HBsAb and HBV DNA levels were moni-
tored. In BALB/c mice injected with pBS-HBV1.3B, the
HBsAg level increased in the first three days but dropped
quickly afterward and all mice became negative at 1 wpi.
However, the HBsAg level in BALB/c mice injected with
pAAV-HBV1.3B declined slowly with time and 75% of the
mice were HBsAg positive at day 10 dpi. HBsAg became
undetectable in all mice at 4 wpi (Figure 3A). In contrast
to BALB/c mice, the HBsAg level decreased much more
slowly after injection of the same plasmids in C57BL/6mice. 50% of C57BL/6 mice injected with pBS-HBV1.3B
were HBsAg-positive at 1 wpi and all mice became nega-
tive at 2 wpi. Moreover, 75% of C57BL/6 mice injected
with pAAV-HBV1.3B were still HBsAg-positive at 2 wpi.
HBsAg remained detectable in 50% of the mice after
10 weeks (Figure 3A). These results confirmed that the
host genetic background as well as the vector backbone
influenced HBV persistence.
In addition, we also compared the kinetics of viremia
between pAAV-HBV1.3B and pAAV-HBV1.2 in the HI
C56BL/6 mouse model. The serum HBV DNA level in
pAAV-HBV1.3B injected mice was higher than that in
pAAV-HBV1.2 injected mice (Figure 2A). However, the
C57BL/6 mice received pAAV-HBV1.3B had a lower posi-
tive rate of HBsAg compared with that received pAAV-
HBV1.2. 20% of the mice are HBsAg positive at week 24
after HI with pAAV-HBV1.3B, which was only half of that
in mice injected with pAAV-HBV1.2 (Figure 3B).
None of the C57BL/6 mice injected with pAAV-HBV1.2
produced HBsAb after 28 dpi, although all of them
produced HBcAb after the day 7 (Table 1). However, 3 of
14 C57BL/6 mice received pAAV-HBV1.3B produced
HBsAb after the 28 dpi. Moreover, the raise of HBsAb in
pAAV-HBV1.3B injected mice was faster than that in
pAAV-HBV1.2. As shown in Table 1, for those mice
producing HBsAb, they were HBsAg negative. All mice
developed HBcAb after 7 dpi. Thus, different replica-
tion competent HBV genomes in the AAV vector may
differ in their ability to establish the persistent replica-
tion in mice.
Impaired HBcAg specific cellular immunity in pAAV-HBV1.2
and pAAV-HBV1.3B injected C57BL/6 mice during initial
activation
Huang et al. (2006) confirmed that the tolerance toward
HBV surface antigen in this model was due to an insuffi-
cient cellular immunity against hepatitis B core antigen.
To confirm this result, HBV-specific CTL responses
against full length HBcAg peptide were detected at 3dpi
and 10 dpi after HI by ELISPOT assay of IFN-γ produ-
cing cells. At 3 dpi we almost could not detect any
significant levels of HBcAg specific IFNγ-producing cells
in the splenocytes (Figure 4A). However, the average
number of IFNγ secreting cells was 463 and 653 in
1× 106 splenocytes in pAAV-HBV1.2 and pAAV-HBV1.3B
injected mice at 10dpi, respectively (Figure 4B). There is
no significant difference between those two groups
(p > 0.05). The result indicates that HBcAg-specific
immune response may play a key role in clearing HBV
infection at early stage in the HI mouse model.
HBxi285 inhibited HBV replication in vitro
To apply RNAi in vivo, the vector based expression of
siRNAs was explored in the HI mouse model. For these
ApAAV-HBV1.3B
70 168 252





























Figure 2 (See legend on next page.)
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Figure 2 HBV replication and gene expression in vivo after HI with pAAV-HBV1.3B or pAAV-HBV1.2. 10 μg of pAAV-HBV1.3B or pAAV-HBV1.2
were injected into the tail veins of C57BL/6 mice. pAAV-HBV1.3B group included 14 mice and pAAV-HBV1.2 group included 9 mice. (A) Real-time
detection of HBV DNA in mouse sera at the indicated time points (the number of the mice≥ 3). (B) Southern blot analysis with 20 mg of total DNA
extracted from liver tissues of the mice HI with pAAV-HBV1.3B or pAAV-HBV1.2 at different time points after HI. All DNA samples were treated with
RNase before subjected to agarose gel electrophoresis. Bands corresponding to the expected size of the input HBV plasmids, relaxed circular (RC) and
single-stranded (SS) HBV DNAs are indicated. (C) Real-time PCR detection of HBV DNA levels in the liver of the mice after HI. (D) Immunohistochemical
staining of the liver sections for HBcAg in hepatocytes of HBsAg-positive or HBsAg-negative mice at day 252 after HI with pAAV-HBV1.3B (1, HBsAg
positive mice and 3, HBsAg negative mice) and at day 340 after HI with pAAV-HBV1.2 (2, HBsAg positive mice and 4, HBsAg negative mice) (Original
magnification: 400X).
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pSuper.basic (pSB) were tested. Two different target
sequences in the HBV x gene were selected and cloned
into the vectors (see Material and Methods).
The antiviral effect of pSR-HBxi314 and pSR-HBxi285
was investigated in vitro. As shown in Figure 5A, the
HBsAg and HBeAg levels decreased by 80.2% and
78.7% when pAAV-HBV1.3B and pSR-HBxi285 were co-
transfected into Huh-7 cells, respectively. However, when
pAAV-HBV1.3B and pSR-HBxi314 were co-transfected
into Huh-7 cells, the HBsAg and HBeAg levels were only
inhibited by 10.5% and 30.3%, respectively. Different
concentrations of pSR-HBxi285 were used to test whether
the antiviral effect was dose-dependent. Figure 5B and C
showed that pSR-HBxi285 inhibited HBsAg and HBeAg
expression as well as HBV DNA in a concentration-
dependent manner in the range of 0.1–0.5 μg. The
0.5 μg dose of pSR-HBxi285 was most effective for the
reduction of HBsAg, HBeAg and HBV DNA in tran-
sient transfection.
To compare the antiviral effects of pSB-HBxi285 and
pSR-HBxi285 in vitro, pAAV-HBV1.3B and different
concentrations of pSB-HBxi285 or pSR-HBxi285 were co-
transfected into Huh-7 cells. Figure 5D shows that pSB-
HBxi285 and pSR-HBxi285 inhibited HBsAg and HBeAg
in a dose-dependent manner. However, there was no
significant difference in their antiviral effect (P > 0.05).
HBxi285 reduced serum HBsAg and HBV DNA levels in
C57BL/6 mice after HI
Based on the previous experiments, 10 μg of pAAV-
HBV1.3B and 10 μg pSB-HBxi285 or pSR-HBxi285 were
co-injected into C57BL/6 mice to determine the antiviral
effect of HBxi285 in vivo. Each group contained 10 mice.
Initially, HBsAg levels in mice were significantly reduced
by HI in the presence of pSB-HBxi285 or pSR-HBxi285
plasmids at 1 dpi (p < 0.05), compared with the control
groups receiving empty vectors (Figure 6A). However,
the HBsAg levels in pSB-HBxi285 treated mice quickly
increased during the follow up and reached the levels of
the control at 14 dpi. In contrast, the HBsAg levels in
pSR-HBxi285 treated mice were inhibited to a signifi-
cantly lower degree before the 28 dpi compared with thecontrol groups (p < 0.05). HBsAg became detectable in
some mice at 42 dpi. It is worthy to note that the major-
ity (7 of 10) of the mice received pSR-HBxi285 were
HBsAg negative during the whole experimental period
(Table 2). HBV DNA concentrations in mouse sera were
determined and were well correlated with HBsAg levels
(Figure 6B). Figure 6C shows that the HBsAg positive
rate in pSB-HBxi285 or pSR-HBxi285 treated mice was
significantly decreased in comparison to the controls at
1 dpi. Thereafter, the positive rate of HBsAg in pSB-
HBxi285 treated mice increased gradually and showed
no significant difference in comparison to the control at
7 dpi. The positive rate of HBsAg in pSR-HBxi285
treated mice remained at a lower level (18.2-27.3%) than
other groups until the 4th week post injection (wpi) but
showed similar levels to the other groups in the 5th wpi.
Consistently, immunostaining of HBcAg in the liver
section of mice after HI demonstrated that the
co-application of pSR-HBxi285 or pBS-HBxi285 aboli-
shed HBcAg expression in the mouse liver at 3 dpi
(Figure 6D). However, HBcAg may become detectable in
the mouse liver which received pSR-HBxi285 similar to
those of control mice 4 weeks after HI. The results indi-
cated that HBxi285 could significantly inhibit the HBsAg
production and HBV replication. However the vector
pSR-HBxi285 was more efficient in reducing HBsAg and
HBV DNA levels than that of pSB-HBxi285.
Discussion
In the present study, an HBV genotype B HI mouse
model was established. After HI with pAAV-HBV1.3B,
HBsAg and HBV DNA were detected in peripheral
blood. Southern blot and immunohistochemical staining
analysis revealed that HBV DNA and HBcAg were
detected in the liver tissue of HBsAg-positive mice.
Different hepatitis B virus genotypes may have distinct
virologic characteristics, which may correlate with anti-
viral curative effects and clinical outcome [29,30]. The
majority of HBV infections are distributed in the Asia-
Pacific region. In these regions, patients are mainly
infected with genotypes B and C. Previous studies
showed that in China and Taiwan, approximately 90% of
patients under thirty-five years old who are infected with
Figure 3 HBV persistence after HI in mouse in dependence on
the mouse genetic backgrounds and the vector backbones.
10 μg of pBS-HBV1.3B or pAAV-HBV1.3B were injected into the tail
veins of BALB/c or C57BL/6 mice. Each group included 5 mice. In
addition, 10 μg pAAV-HBV1.3B or pAAV-HBV1.2 were injected into
the tail veins of C57BL/6 mice to test the ability of these two
plasmids to establish persistent HBV replication. pAAV-HBV1.3B group
included 14 mice and pAAV-HBV1.2 group included 9 mice. (A) The
positive rate for serum HBsAg in C57BL/6 or BALB/c mice receiving
pBS-HBV1.3B or pAAV-HBV1.3B injections at indicated time points
after injection. The data were analyzed by Kaplan–Meier analysis,
and the differences between each group were statistically significant
(p = 0.004, <0.05). (B) The positive rate for serum HBsAg in C57BL/6
mice receiving pAAV-HBV1.3B or pAAV-HBV1.2 injection. The data
were analyzed by Kaplan–Meier analysis, and the differences
between two groups were statistically significant (p = 0.017, <0.05).
The cutoff value for determining HBsAg-positivity was 0.1.
Table 1 Appearance of anti-HBc and anti-HBs antibodies
in C57BL/6 mice after HI of HBV plasmids
Anti-HBc antibodies Anti-HBs antibodies
HBV clone Day 1 day 7 Day 7 Day 28 Day 168
pAAV-HBV1.3B 0/14 14/14 0/14 3/14 6/8
pAAV-HBV1.2 0/9 9/9 0/9 0/9 4/8
The number of C57BL/6 mice in each group positive for anti-HBc or anti-HBs
antibodies after injected hydrodynamically with 10 μg of pAAV-HBV1.3B or
pAAV-HBV1.2 plasmids. All the mice with HBsAb are HBsAg negative.
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HBV genotype B infection [30,31]. Now, we have a
system at hand to examine the replication of HBV
genotype B clone in the mouse models.
In present study, we investigated the effect of the HBV
genome length on HBV replication competence to find
the optimal structure of replication competent HBVgenotype B clone. Three clones with 1.1, 1.2 and 1.3 fold
over length HBV genotype B genomic DNA were
constructed based on the pBluescript II KS (+) vector.
Schematic representation of the 1.1, 1.2 and 1.3 fold
HBV genome used in this study are shown in Additional
file 1: Figure S1B. The plasmid with 1.3 fold genomes
containing a complete extra copy of the entire EnhI, Enh
II and HBx gene as shown in Additional file 1: Figure S1B
which is a suitable HBV construct for transfection and
HI experiments. When the cloned plasmids were
transfected into Huh-7 cells or hydrodynamically injec-
ted into BALB/c mice, pBS-HBV1.3B demonstrated
significantly high-level replication and gene expression
in comparison to pBS-HBV1.1B and pBS-HBV1.2B
(Figure 1). Increasing the length of the 1.3 fold over
length HBV genome did not further improve the repli-
cation competence. Nevertheless, the replication com-
petence declined and could not reach the original level
of HBV in nature infection state when the length is less
than 1.2 fold of the HBV genome. Durantel et al. and
other groups used 1.1 fold over length HBV genome for
studies on drug resistant HBV isolates [32,33]. How-
ever, they added strong foreign promoters to enhance
the HBV transcription and replication. In conclusion,
the 1.3 fold HBV genome length containing a complete
extra copy of the entire EnhI, EnhII and HBx gene as
described in the present study could be regarded as an
optimal length for HBV replication constructs with the
authentic HBV sequence, independent on a foreign
promoter.
To establish a persistent replication HBV mouse
model with the HBV genotype B clone, 1.3 fold over
length HBV genotype B genome was sub-cloned into the
pAAV-MCS vector and introduced into C57BL/6 mice
by HI. Huang et al. (2006) found that the AAV vector
contributed to the persistence of HBV in mouse liver.
Therefore, we used a similar vector pAAV-MCS, to con-
struct HBV genotype B replicational clone in this study.
This vector also has the ITR (inverted terminal repeats)
structure, which was considered as a key factor for its
stable existence in vivo by integration or non-integration
way. Because the vector does not express other proteins
except that encoded by the target genes, the vector back-
bone has no direct effect on the immune system.
Figure 4 Specific T-cell responses to HBcAg epitopes in mice
after HI. The specific T-cell responses to the full length HBcAg
peptide after HI. The number of HBcAg specific IFNγ secreting cells
in 1× 106 splenocytes in pAAV-HBV1.2 and pAAV-HBV1.3B injected
mice at 3dpi (A) and 10dpi (B) by IFNγ ELISPOT assay in the
presence of 0.5 μg/ml full length HBcAg peptide. The experiments
were done in duplicate. The data were analyzed by t test, and there
is no significant differences between those two groups (p > 0.05).
Li et al. Virology Journal 2013, 10:214 Page 8 of 15
http://www.virologyj.com/content/10/1/214After HI, the mice presented higher HBV DNA level,
but a lower positive rate for HBsAg in serum compared
with pAAV-HBV1.2 injected mice [12]. Apparently, HBV
replication is not strictly correlated with HBsAg produc-
tion, as known for patients [34-38]. The result indicated
that the model is more robust when pAAV-HBV1.2
genotype A is used as compared with pAAV-HBV1.3B.
Huang et al. (2006) confirmed that the tolerance toward
HBV surface antigen in this model was due to an insuffi-
cient cellular immunity against hepatitis B core antigen,
as documented in humans. We repeated some experi-
ments and obtained the same results (Figure 4A and B).
The difference in plasmid backbones between both
clones needs to be investigated further.The antigenemia and production of HBV particles
were highly reproducible in the persistent HBV replica-
tion mouse model based on HI making this model
appropriate for the evaluation of the efficacy of anti-viral
drugs. Therefore, we further investigated the anti-viral
effect of vector-expressed HBx siRNA in this model. Co-
application of the HBx siRNA expression plasmids
treatment of these mice induced a significant inhibition
of HBV replication and expression. When pAAV-HBV1.3B
was co-injected into the tail veins of C57BL/6 mice with
either pSB-HBxi285 or pSR-HBxi285, HBV expression
and replication were efficiently inhibited. There are two
methods commonly used to silence target genes. Chemical
synthesized siRNAs have a good specificity and are
commonly used on cells by transfection. However, such
siRNAs, if not chemically modified, are instable and
eliminated rapidly in vitro and in vivo. The production of
siRNAs, particularly with specific chemical modifications,
is very expensive. Another approach is to use siRNA
transcription vectors. The disadvantages to use such as
retroviral vectors are, for example, the lower transfection
efficiency and slow action compared with chemical
synthesized siRNA. However, the vector-based approach
has some advantages regarding the stability and costs. It is
important to prolong the expression of siRNAs to main-
tain the inhibition of HBV. Moreover, when the pSuper.
Retro vector was transfected into a packaging cell line
such as 293 T cell line, it could produce retroviral
supernatants and obtain a higher rate of stable cell inte-
gration (The Manual of pSuper RNAi system, OligoEngine,
Washington, USA) [39,40].
HI of naked plasmid DNA is a simple yet effective
in vivo gene delivery method into hepatocytes. The early
reports suggested that a large portion of hepatocytes
could be reached with this technique [41-44]. Therefore,
it could be a useful method to test the efficacy of RNAi
based antiviral therapies in the mouse model. Certainly,
there is still a challenge how to transfer the knowledge
gained in this system into human situation.
In this study, non-viral (pSuper.Basic) and retroviral
vectors (pSuper.Retro) were used to construct shRNA
(small hairpin RNA) expression plasmids [45] targeting
the HBx gene of HBV. The pSuper.Retro vector contains
the H1 promoter which is a RNA polymerase III like
promoter and can transcript shRNA steadily, and
showed persistent inhibitory effect in vitro [46,47]. The
pSuper.Retro vector includes 3′ and 5′ terminal LTR
structure of murine stem cell virus. The pSuper.Retro
vectors can be transfected into a packaging cell line to
produce retroviral supernatants and obtain a higher rate
of stable cell integration. In addition, this vector contains
an incomplete packaging signal and could not produce
recombinant retroviruses (The Manual of pSuper RNAi
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1      2      3     4      5 C
pAAV-HBV1.3B     (μg) 0.5 0.5 0.5 0.5 
pSB-HBxi285      (μg) – 0.1 0.3 0.5
pSB vector          (μg) 0.5 0.4 0.2 –
pAAV-HBV1.3B     (μg) 0.5 0.5 0.5 0.5 
pSR-HBxi285      (μg) – 0.1 0.3 0.5
pSR vector          (μg) 0.5 0.4 0.2 –
D
Figure 5 The effect of HBx iRNA on HBV gene expression and replication in vitro. Different concentrations of HBx iRNA and pAAV-HBV1.3B
were co-transfected into Huh-7 cells which were seeded in 24-well plates at approximately 60% confluence. The concentrations of the plasmids
were indicated in the Tables. (A) HBsAg and HBeAg levels in the cell culture supernatants of cells co-transfected with 0.5 μg of pAAV-HBV1.3B-
and 0.5 μg of pSR-HBxi314- or pSR-HBxi285. (B) HBsAg and HBeAg levels in the cell culture supernatants of cells co-transfected with pAAV-HBV1.3B and
0, 0.1, 0.3, or 0.5 μg of pSR-HBxi285. (C) HBV replicative intermediates in Huh-7 cells transfected with pAAV-HBV1.3B and 0, 0.1, 0.3, or 0.5 μg of pSR-
HBxi285. (D) A comparison of the inhibition rate of HBsAg in the cell culture supernatants of cells co-transfected with pAAV-HBV1.3B- and pSB-HBxi285-
or pSR-HBxi285.
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system, OligoEngine, Washington, USA) and used to
compare the stability with pSuper.Retro in vivo. The
difference of both vectors in the gene silencing effects is
likely due to their stability in vivo. HBx protein plays an
important role in HBV replication and HBV induced
HCC [26,48]. Therefore, HBx became a good target gene
for gene silencing in recent years. Importantly, as all
HBV RNA transcripts share the same sequence in the
HBx due to its unique transcription mechanism, siRNAs
targeting the HBx region actually knock down all HBV
RNAs, as shown in the previous studies [28,49,50].
The result showed that the siRNA targeting the region
nt 285–303 of the HBx coding region has a stronger
antiviral effect than that targeting the region nt 314–332. It is known that siRNA-specific features such as
low G/C content, a bias towards low internal stability at
the sense strand 3′-terminus, lack of inverted repeats,
and sense strand base preference, interaction with the
cellular machinery called RISC and so on are likely to
contribute to efficient RNAi process. The relative influ-
ence of these parameters is not fully understood and
now under investigation by many groups [51-56]. When
pAAV-HBV1.3B and pSB-HBxi285 or pSR-HBxi285 was
co-injected into the tail veins of C57BL/6 mice, HBV
expression and replication could be significantly inhibi-
ted by the first week. Thereafter, the antiviral effect
declined in the pSB-HBxi285 treated mice, whereas the
antiviral effect of pSR-HBxi285 was maintained for at
























Figure 6 The effect of HBxi285 on HBV gene expression and
replication in vivo. 10 μg pAAV-HBV1.3B and 10 μg pSB-HBxi285,
pSR-HBxi285 or control plasmids were co-injected into the tail veins
of C57BL/6 mice. Each group included 10 mice. (A) HBsAg levels, (B)
HBV DNA and (C) the positive rate of HBsAg in the serum of C57BL/
6 mice treated with pAAV-HBV1.3B and pSR-HBxi285 or pSB-HBxi285.
Value 0 of HBV DNA means the copy number of HBV DNA is lower
than detection limit. The data were analyzed by one-way ANOVA,
and the differences were statistically significant (# : p < 0.05 pSR-
HBxi285 group vs. pSR-HBxicon group; * : p < 0.05 pSR-HBxi285
group vs. pSB-HBxi285 group by one-way ANOVA) (D)
Immunohistochemical staining for HBcAg in hepatocytes of C57BL/6
mice treated with pSR-HBxi285, pSB-HBxi285, pSR-HBxicon or pSR
vector separately at 3 day post injection (1–4) and C57BL/6 mice
treated with pSR-HBxi285 or pSR-HBxicon in the 4th wpi (5–6)
(Original magnification: 200X).
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much more effectively inhibit HBV expression and
replication than the non-viral vector based HBx siRNA
expression plasmids. Among the mice which received
pSR-HBxi285, HBV replication was completely suppres-
sed in the majority of mice, as no HBsAg was detectable
for the whole experimental period of 16 weeks. However,
HBV gene expression and replication may resume in
some mice despite an initial delay, indicating that transi-
ent suppression of HBV replication by HBx siRNA may
also fail to clear HBV completely in some individuals. It
is worth to mention that the change of serum HBsAg
and HBV DNA in the mice after the application with
HBx siRNAs occurred with different kinetics. The reason
may be the different requirement of HBsAg translation
and HBV DNA replication. It is well established that
only a small fraction of HBsAg is required for virion
production [57]. In the patients with chronic HBV infec-
tion, HBV DNA loads do not correlated with HBsAg
[58]. Our results suggest that measures to prolong the
antiviral effect of the siRNA should be investigated in
future studies.
Conclusions
In summary, our established HBV genotype B HI mouse
model is reliable and could be applied for studies on
genetic and antiviral research of chronic HBV infection.
The retroviral vector based HBx siRNA expression
plasmids could efficiently inhibit HBV expression and
replication, suggesting that an siRNA-based treatment
strategy may be an additional therapeutic option for
future clinical use in patients with chronic HBV
infection.
Materials and methods
Construction of replication competent HBV genotype B
clones
The plasmid pAAV-HBV1.2 which contains an 1.2 fold
over-length HBV genotype A genome (nt 1400-3182-1987)
Table 2 HBsAg detection in HBxi285 treated and control mice
Mouse group Persistent negative Negative→ positivea Persistent positive or positive→ negativeb
pSR-HBxi285 7/10 2/10 1/10
pSB-HBxi285 3/10 4/10 3/10
pSR-HBxicon 3/10 0/10 7/10
pSR vector 1/10 0/10 9/10
a Those mice with initial negative HBsAg became HBsAg positive. b Those mice with initial positive HBsAg became HBsAg negative during the whole experimental
period of 16 weeks after HI. The cutoff value for determining HBsAg-positivity was 0.1.
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http://www.virologyj.com/content/10/1/214[12], was kindly provided by Prof. Pei-Jer Chen. The plas-
mid pUC-HBV containing a full length genotype B HBV
genome (1820-3215-1824 nt, GenBank accession number:
AY220698.1) was kindly provided by Prof. Jiming Zhang
(Fudan University, China). The construction procedure of
pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B is shown
in Additional file 1: Figure S1A. First, the large fragments
of the genotype B HBV DNA nt 1658-3215-247, nt 1360-
3215-247 and nt 1040-3215-247 were amplified by PCR
with primers hbv1.1LF (tagged with PstI site) and hbvLR
(tagged with XbaI site), hbv1.2LF (tagged with PstI site)
and hbvLR, hbv1.3LF (tagged with PstI site) and hbvLR,
rsepectively. Those three fragments were inserted into the
pBluescript II KS (+) (Invitrogen, Camarillo, USA) vector
digested with PstI and XbaI. The small fragment of HBV
DNA nt 247–1986 was amplified using primers hbvSF
(tagged with XbaI site) and hbvSR (tagged with SacI site),
and was inserted into the the pBluescript II KS (+) vector
digested with XbaI and SacI. The resulting plasmids
including nt 1658-3215-1986, nt 1360-3215-1986 and nt
1040-3215-1986 of HBV genome were named as pBS-
HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B, respectively.
Schematic representation of the 1.1, 1.2 and 1.3 fold HBV
genome are shown in Additional file 1: Figure S1B. All
primers used to amplify HBV fragments are listed in
Table 3. All DNA fragments in the final transfer vectors
were amplified with Pyrobest DNA polymerase (TAKARA,
Dalian, China) and cloned into the commonly used, com-
mercially available pGEM-T vector (Promega, Madison,
USA) for PCR cloning and sequencing. The correctness of
the sequences of cloned DNA fragments were confirmed
by sequencing. To establish HI mouse model with a
high positive rate of HBsAg, we cloned the 1.3 fold
HBV genome into the vector including the backbone of
adeno-associated virus, similar to the described proced-
ure [12]. The HBV 1.3 fold over length genome DNA
was amplified from pGEM-HBV1.3B with primers
hbv1.3 F (tagged with NotI) and hbv1.3R (tagged with
NotI), and sub-cloned into the NotI site of the pAAV-
MCS vector (Agilent technologies, La Jolla, USA). The
resulting plasmid was designated as pAAV-HBV1.3B.
The construction procedure of pAAV-HBV1.3B is
shown in Additional file 1: Figure S1C.Cell culture and transfection
Huh-7 cells (Human hepatocarcinoma cell line) were
maintained in 1640 medium supplemented with 10% of
fetal bovine serum, 100 μg/ml penicillin and 100 μg/ml
streptomycin. Cells were seeded in 24-well plates at
approximately 60% confluence. After 24 h, cells were
transfected with Lipofectamine 2000 (Invitrogen, Camarillo,
USA) according to the manufacturer’s instructions. For
pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B, 0.8 μg of
plasmid DNA and 2 μl of lipofectamine 2000 were
placed in each well of a 24-well plate. The efficiency of
our transfection procedure was verified and controlled
by transfection of a GFP expressing vector, as described
previously [59].
To prove the antiviral effect of HBx siRNA, 0.5 μg of
pAAV-HBV1.3B and 0.5 μg of pSR-HBxi314 or pSR-
HBxi285 were co-transfected into Huh-7 cells. The dose
dependent antiviral effect of pSR-HBxi285 was tested by
co-transfection of 0.5 μg pAAV-HBV1.3B with 0, 0.1, 0.3
and 0.5 μg of pSR-HBxi285 into Huh-7 cells. To com-
pare the antiviral effects of pSB-HBxi285 and pSR-
HBxi285, 0.5 μg pAAV-HBV1.3B combined with 0, 0.1,
0.3 and 0.5 μg of pSB-HBxi285 or pSR-HBxi285 were
co-transfected into Huh-7 cells in parallel. All cell trans-
fection experiments were performed three times.
HI experiments
The replication competence of the overlength HBV
genomes in vivo was tested by HI with pBS-HBV1.1B,
pBS-HBV1.2B or pBS-HBV1.3B plasmids in BALB/c
mice (female, 6–8 weeks old, from the breeding colonies
of the experimental animal center in Hubei Province,
China), with 10 mice per group. C57BL/6 mice (male,
6–8 weeks old, from the breeding colonies of the experi-
mental animal center in Shanghai, China), were subjec-
ted to HI with pAAV-HBV1.3B or pAAV-HBV1.2 to test
the ability of these plasmids to establish persistent HBV
replication. pAAV-HBV1.3B group included 14 mice and
pAAV-HBV1.2 group included 9 mice. To investigate the
factors affecting HBV persistent in the mouse liver, we
injected pBS-HBV1.3B or pAAV-HBV1.3B into BALB/c or
C57BL/6 mice separately, with 5 mice per group. HI
experiments were carried out as described previously [17],
Table 3 Primers for amplification of 1.3, 1.2, and 1.1 fold over length HBV replication-competent clones
Primer Position Sequence Referencea
hbv1.1LF HBV 1658-1677 5′-aac tgc aga aga gga ctc ttg gac ttt c-3′ AY220698.1
hbv1.2LF HBV 1360-1379 5′-aac tgc aga gta tac atc att tcc atg g-3′ AY220698.1
hbv1.3LF HBV 1040-1058 5′-tgc aac tgc agt gga tat cct gct tta atg-3′ AY220698.1
hbvLR HBV 253-233 5′-gct cta gac tct gtg gta ttg tga-3′ AY220698.1
hbvSF HBV 247-264 5′-ggc tag tct aga ctc gtg gtg g-3′ AY220698.1
hbvSR HBV 1986-1969 5′-acc gag ctc tcg aat aga agg aaa gaa-3′ AY220698.1
hbv1.3 F pGEM-T 4-39 5′-ata aga atg cgg ccg ccg aat tgg gcc cga cgt cg-3′ X65308.2
hbv1.3R pGEM-T 117-81 5′-ata gtt tag cgg ccg cgt tgg gag ctc tcc cat atg-3′ X65308.2
Restriction sites are shown in italics. The gene sequences included in the primers are indicated by underling. a The Genbank accession numbers of the used
reference sequences are given.
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veins of mice in a volume of 0.9% NaCl, equivalent to 8%
of the mouse body weight. The total volume was delivered
within 5–8 s. For HBx siRNA experiments, 10 μg pAAV-
HBV1.3B and 10 μg pSB-HBxi285, pSR-HBxi285 or con-
trol plasmids were co-injected into the C57BL/6 mice.
Each group included 10 mice. The control mice were
injected only with the volume of 0.9% NaCl, equivalent to
8% of the mouse body weight.
Detection of HBsAg, HBeAg, HBsAb and HBcAb
Culture supernatants of pBS-HBV1.1B, pBS-HBV1.2B or
pBS-HBV1.3B transfected Huh-7 cells were harvested at
48 h post-transfection. Mouse sera were collected at the
1d (day), 3d, 7d, 10d, 2w (week), 3w, 4w, 5w, 6w, 7w,
8w, 9w, 10w… after HI. The analysis of HBsAg (ng/ml),
HBeAg (NCU/ml, National Clinical Unit/ml), HBsAb
(mIU/ml, Milli-International Units) and HBcAb (S/Co,
Sample/Cutoff value) levels were determined by using
the Architect system and CMIA kits (Abbott Labora-
tories, Wiesbaden-Delkenheim, DE) according to the
manufacturer’s instructions.
Isolation and analysis of HBV DNA in mouse sera
HBV DNA was extracted from 40 μl of mouse serum sam-
ples. The protocol was described previously [17]: 40 μl of
samples were treated with 10 μg DNase I for 16 h at 37°C.
100 μl of lysis buffer (20 mM Tris–HCl, 20 mM EDTA,
50 mM NaCl and 0.5%SDS) containing 50 μg proteinase
K were added. After incubation at 65°C for 3 h, viral DNA
was isolated by phenol/chloroform extraction and ethanol
precipitation. The DNA pellet was rinsed with 70% etha-
nol and resuspended in 10 μl of ddH2O.
The quantification of HBV DNA was performed by
using a routine real time PCR procedure, described
previously [34,60-64]. The HBV copy numbers were
determined by SYBR Green Real time PCR Master Mix
(commercially available assay kit, TOYOBO, Osaka, Japan).
Melt curve analysis and agarose gel electrophoresis were
used to verify the specificity of the real-time PCR. Thefollowing primers were used: forward primer: 5′-CTG CAT
CCT GCT GCT ATG-3′ (nt 408–425), reverse primer: 5′-
CAC TGA ACA AAT GGC AC-3′ (nt 685–701) according
to the reference sequence with Genbank accession number
(AY220698.1). Serum containing a known concentration of
HBV DNA was used as a positive control.
Immunohistochemistry
The liver tissue was taken from the mice receiving HI
with pBS-HBV1.1B, pBS-HBV1.2B or pBS-HBV1.3B at
7 day post injection (dpi) and the mice receiving HI with
pAAV-HBV1.3B at 70 dpi, 168 dpi and 252 dpi or
pAAV-HBV1.2 at 70 dpi, 168 dpi and 340 dpi, which
was then used for immunohistochemical staining of the
HBcAg in hepatocytes. The liver tissue of the mice
received 0.9% NaCl was used as negative control. Liver
tissue was collected from the mice and embedded in
paraffin. Intrahepatic HBcAg was visualized by immu-
nohistochemical staining with rabbit anti-HBc (Dako) of
the liver tissue sections. The liver tissue sections were
also stained with hematoxylin.
Purification and Southern blot analysis of HBV DNA from
the liver tissue of mice
Total DNA from the pAAV-HBV1.3B and HBx siRNA ex-
pression plasmids co-transfected Huh-7 cells and the liver
tissue of mice was isolated using commercial kits
(OMEGA, Norcross, USA). The isolated HBV DNA was
subjected to agarose gel electrophoresis followed by dena-
turation and Southern blot analysis. All DNA samples were
treated with RNase before gel electrophoresis. HBV DNA
was detected by hybridization with a digoxigenin (DIG)
(Roche, Lewes, UK)-labeled full length HBV probe. The
hybridization signals were visualized on x-ray film using an
alkaline phosphatase-anti-DIG-Fab conjugate in the pres-
ence of the chemiluminescence substrate CDP-Star (Roche).
Enzyme-Linked Immunospot (ELISPOT) assay
ELISPOT assay was carried out using the mouse IFN-γ
precoated ELISPOT Kit (Dakewe, Shenzhen, China)
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well flat-bottomed microtiter plates were preincubated
with the coating antibody (anti-IFN-γ monoclonal
antibody) at 4°C overnight and blocked for 2 hr at 37°C.
Mouse splenocytes at the density of 1 × 106 cells per well
were added to wells in triplicate with final concentration
of 0.5 μg/ml full length HBcAg peptide (ProSpec, Ness-
Ziona, Israel) separately and incubated at 37°C, 5% CO2
for 24 hr. 1 μg/ml of ConA (Sigma, St. Louis, USA) was
used as positive control. Thereafter, cells were removed.
Wells were washed ten times with PBS containing 0.05%
Tween-20 (PBS-T) and incubated with 100 ml of biotiny-
lated anti-IFNγ antibody for 1 hr. The plates were washed
again with PBS-T and incubated with 50 ml HRP-strepto-
avidin solution at 37°C for 1 hr. Spot-forming cells were
counted and analyzed with an ELISPOT plate reader
(BioReader 4000, Biosys, Germany). Results were presen-
ted as spot-forming cells per 1 × 106 cells.Construction of HBx siRNA expression plasmids
Two pairs of DNA sequences targeting the nt 285–303
and nt 314–332 of the HBx coding region of HBV
(genotype B, adw) were designed in accordance with the
protocols for the siRNA expression vectors pSuper.Basic
and pSuper.Retro (OligoEngine, Washington, USA), and
the two RNAi design server (http://www.ambion.com/
techlib/misc/siRNA_tools.html and http://www.dharmacon.
com/DesignCenter). The DNA sequences were as follows:
HBxi314F, 5′-GAT CCC CCG ACC GAC CTT GAG GCA
TAT TCA AGA GAT ATG CCT CAA GGT CGG TCG
TTT TTA-3′, HBxi314R, 5′-AGC TTA AAA ACG ACC
GAC CTT GAG GCA TAT CTC TTG AAT ATG CCT
CAA GGT CGG TCG GGG-3′; HBxi285F, 5′-GAT CCC
C GA GGA CTC TTG GAC TTT CAT TCA AGA GAT
GAA AGT CCA AGA GTC CTC TTT T TA-3′,
HBxi285R, 5′-AGC TTA AAA AGA GGA CTC TTG
GAC TTT CAT CTC TTG AAT GAA AGT CCA AGA
GTC CTC GGG-3′, the HBx iRNA control sequences
were: HBxiconF, 5′-GAT CCC CGC ACC TAT AAC AAC
GGT AGT TCA AGA GAC TAC CGT TGT ATA GGT
GCT TTT TA-3′, HBxiconR, 5′-AGC TTA AAA AGC
ACC TAT AAC AAC GGT AGT CTC TTG AAC TAC
CGT TGT TAT AGG TGC GGG-3′ (the sequences tar-
geting HBx gene are shown in italics). The single
strand DNA products were purchased from Invitrogen
(Shanghai, China).
The above complementary sequences were phos-
phorylated and ligated into BglII and HindIII digested
pSuper.Basic or pSuper.Retro vector. The resulting
plasmids were named as pSB-HBxi314, pSB-HBxi285,
pSB-HBxicon, pSR-HBxi314, pSR-HBxi285 and pSR-
HBxicon. The clones were sequenced to confirm the
correctness of the sequences.Statistical analysis
The data were evaluated by Student’s t-test or one-way
ANOVA followed by Tukey’s post hoc test. The statis-
tical significance of the data was considered at p < 0.05.Approval of the ethics committee
The animal experiments were carried out in concor-
dance with the guidelines established by the Institutional
Animal Care and Use Committee at the Huazhong
University of Science and Technique and the Tongji
Hospital of Tongji Medical College. The mice used in
this study were anesthetized with ketamine and xylazine.Additional files
Additional file 1: Figure S1. Construction procedure for the pBS-HBV1.1B,
pBS-HBV1.2B, pBS-HBV1.3B and pAAV-HBV1.3B vectors. (A) The fragments
containing 1.1, 1.2 and 1.3 fold over length HBV genomes were amplified
from the plasmid pUC-HBV containing a full length genotype B HBV
genome (1820-3215-1824 nt, GenBank accession number AY220698.1) and
inserted into the PstI and SacI sites of the plasmid pBluescript II KS (+). (B)
Schematic representation of the 1.1, 1.2 and 1.3 fold HBV genome used in
this study are shown. HBV ORFs as well as enhancers are indicated in
different patters. (C) The HBV 1.3 fold over length genome DNA was
amplified from pGEM-HBV1.3B and sub-cloned into the NotI site of the
pAAV-MCS vector.
Additional file 2: Figure S2. Identification of pBS-HBV1.1B, pBS-HBV1.2B
and pBS-HBV1.3B. pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B were
identified by restriction enzyme analysis. Lines 1/9: 1 kb DNA ladder;
Lines 2–4: pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B were digested with
PstI and SacI respectively; Lines 5: pBluescriptII KS (+) was digested with
PstI and SacI; Lines 6–8: pBS-HBV1.1B, pBS-HBV1.2B and pBS-HBV1.3B were
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